CatalystMarker
← board

CPHI

distress 6/10 · elevated risk
$1.83+7%today-77% from 52w high
chinapharmaholdings.com215 employeesHaikou, ChinaDrug Manufacturers - Specialty & Generic
Revenue
pre-revenue
Liquidity
$0M
Runway
Shares 1y
+1142%

Price & events

+45.3% over 6M
$0.52$4.31$8.10Jan 26Apr 26Jul 2693.6Mdilution: 424B5 offering (2026-07-23)financing: 8-K private_placement (2026-03-03)financing: 8-K private_placement (2026-02-10)
CatalystRating changeDilutionFinancingdashed = today
+7.0%
1D
+48.8%
1W
+161.5%
1M
+210.2%
3M
+47.6%
6M
+0.6%
1Y
-29.6%
2Y
-99.5%
5Y
-99.3%
All

Overview

Market Cap
$74.16M
Volume
5.76M
52 Week Range
$0.52 – $8.10
Total Shares
40.52M
Float Shares
800.72K
Short %
0.09%
% Held by Insiders
95.16%
% Held by Institutions
0.06%
RVOL
0.70x
Beta
1.15

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 40,522,002 · 0 offerings/1y · 4 PIPEs
  • 2026-07-23424B5offering
  • 2026-03-038-Kprivate_placement
  • 2026-02-108-Kprivate_placement
  • 2025-12-238-Kprivate_placement
  • 2025-12-108-Kprivate_placement
  • 2024-12-138-Kmaterial_agreement
  • 2024-12-13424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.